Closing the Gap: Treating Hypertension in Women

Hypertension is a common and readily modifiable risk factor for cardiovascular and cerebrovascular disease. Despite extensive clinical trial results and efforts to increase public awareness, it remains inadequately controlled in the general population. Women are particularly vulnerable. Recent data indicate both a growing prevalence of hypertension, particularly in the postmenopausal and African American populations, and significantly lower rates of adequate blood pressure control relative to men. Patient sex has an important influence on the nature of the disease, its management, and outcomes. This review will focus on sex-specific factors that contribute to hypertension in women, and current patterns and efficacy of treatment. In addition, we will highlight evidence-based options for antihypertensive treatment in women.

[1]  L. Borrell,et al.  Social disparities in periodontitis among United States adults 1999-2004. , 2008, Community dentistry and oral epidemiology.

[2]  B. Egan,et al.  Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial , 2008, Journal of hypertension.

[3]  A. Pose-Reino,et al.  [Should beta-blockers remain first choice in the treatment of primary hypertension?]. , 2007, Medicina clinica.

[4]  W. Frishman,et al.  Direct Inhibition of Renin as a Cardiovascular Pharmacotherapy: Focus on Aliskiren , 2007, Cardiology in review.

[5]  C. Pepine,et al.  Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: findings from INVEST. , 2007, Journal of women's health.

[6]  S. Solomon,et al.  Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial , 2007, The Lancet.

[7]  S. Blair,et al.  Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. , 2007, JAMA.

[8]  J. Jordan,et al.  Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension , 2007, Hypertension.

[9]  Rowena J Dolor,et al.  Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. , 2007, Journal of the American College of Cardiology.

[10]  I. Reid,et al.  The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women , 2007, Osteoporosis International.

[11]  A. LaCroix,et al.  Prehypertension and Cardiovascular Disease Risk in the Women's Health Initiative , 2007, Circulation.

[12]  C. Lau,et al.  Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999–2004 , 2007, Hypertension.

[13]  J. Manson,et al.  Dietary magnesium intake and risk of incident hypertension among middle-aged and older US women in a 10-year follow-up study. , 2006, The American journal of cardiology.

[14]  B. Davis,et al.  Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2006, Archives of internal medicine.

[15]  S. Oparil Women and Hypertension: What Did We Learn from the Women’s Health Initiative? , 2006, Cardiology in review.

[16]  W. Vongpatanasin,et al.  Estrogen and hypertension , 2006, Current hypertension reports.

[17]  J. Laragh,et al.  The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy , 2006, Hypertension.

[18]  G. Bakris,et al.  Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review , 2006, Hypertension.

[19]  F. McAlister,et al.  Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis , 2006, Canadian Medical Association Journal.

[20]  L. Raij,et al.  Surgical Menopause Increases Salt Sensitivity of Blood Pressure , 2006, Hypertension.

[21]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[22]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. , 2006, Circulation.

[23]  B. Levine,et al.  Hypertension and antihypertensive therapy in elderly women: how much do we really know? , 2006, Hypertension.

[24]  L. Newby,et al.  Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. , 2005, American heart journal.

[25]  W. Willett,et al.  Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort , 2005, BMJ : British Medical Journal.

[26]  A. Mitchell,et al.  [Women and hypertension]. , 2005, Herz.

[27]  D. Lloyd‐Jones,et al.  Hypertension in adults across the age spectrum: current outcomes and control in the community. , 2005, JAMA.

[28]  S. Oparil,et al.  Gender and Blood Pressure , 2005, Journal of clinical hypertension.

[29]  E. Rimm,et al.  Folate intake and the risk of incident hypertension among US women. , 2005, JAMA.

[30]  B. Psaty,et al.  Association between cardiovascular outcomes and antihypertensive drug treatment in older women. , 2004, JAMA.

[31]  S. Kjeldsen,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The value randomised trial☆ , 2004 .

[32]  T. Lumley,et al.  Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. , 2004, JAMA.

[33]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[34]  G. Bakris,et al.  Differential effects of calcium antagonist subclasses on markers of nephropathy progression. , 2004, Kidney international.

[35]  J. Bella,et al.  Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study , 2004, Journal of Human Hypertension.

[36]  Constance K Haan,et al.  Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[37]  S. Oparil,et al.  Essential hypertension in women , 2004, Blood pressure.

[38]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[39]  Thomas Lumley,et al.  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. , 2003, JAMA.

[40]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[41]  S. Port Age-specific relevance of usual blood pressure to vascular mortality , 2003, The Lancet.

[42]  E. Schiffrin,et al.  Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. , 2003, Archives of internal medicine.

[43]  Tosha B. Wetterneck,et al.  Prescribing Oral Contraceptives for Women Older Than 35 Years of Age , 2003, Annals of Internal Medicine.

[44]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[45]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[46]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[47]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[48]  Sudha Seshadri,et al.  Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. , 2002, JAMA.

[49]  A. Gavazzi,et al.  [Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[50]  Jiang He,et al.  Effects of Alcohol Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials , 2001, Hypertension.

[51]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[52]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[53]  J. Fleg,et al.  Hormone Replacement Therapy and Longitudinal Changes in Blood Pressure in Postmenopausal Women , 2001, Annals of Internal Medicine.

[54]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[55]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[56]  J F Reckelhoff,et al.  Gender Differences in the Regulation of Blood Pressure , 2001, Hypertension.

[57]  M E Safar,et al.  Comparative effects of aging in men and women on the properties of the arterial tree. , 2001, Journal of the American College of Cardiology.

[58]  J. Williamson,et al.  Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials , 2000, The Lancet.

[59]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[60]  J. Manson,et al.  Hypertension and Its Treatment in Postmenopausal Women: Baseline Data from the Women’s Health Initiative , 2000, Hypertension.

[61]  F Gueyffier,et al.  Pharmacotherapy for hypertension in women of different races. , 2000, The Cochrane database of systematic reviews.

[62]  A. Chobanian,et al.  National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure : a critical review of current scientific evidence. , 2000, Hypertension.

[63]  P. Whelton,et al.  Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. , 2000, Hypertension.

[64]  P. Whelton,et al.  Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. , 2000, Hypertension.

[65]  K. Kerlikowske,et al.  Efficacy of treating hypertension in women , 1999, Journal of General Internal Medicine.

[66]  M. Moser,et al.  Why are physicians not prescribing diuretics more frequently in the management of hypertension? , 1998, JAMA.

[67]  J. Polónia,et al.  Low‐dose oral contraceptives and 24‐hour ambulatory blood pressure , 1997, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[68]  N. Poulter,et al.  Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994 , 1997, Journal of hypertension.

[69]  J. Cutler,et al.  Effect of Antihypertensive Drug Treatment on Cardiovascular Outcomes in Women and Men , 1997, Annals of Internal Medicine.

[70]  M. Alderman,et al.  Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients , 1997, The Lancet.

[71]  J. Manson,et al.  Prospective study of oral contraceptives and hypertension among women in the United States. , 1996, Circulation.

[72]  M. Elstein,et al.  Low dose combined oral contraceptives , 1995, British journal of obstetrics and gynaecology.

[73]  B. Stricker,et al.  Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. , 1995, Journal of clinical epidemiology.

[74]  D. Sackett,et al.  The number needed to treat: a clinically useful measure of treatment effect , 1995 .

[75]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[76]  L. Wilkins A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[77]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[78]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[79]  M. Alderman,et al.  Blood Pressure Management: Individualized Treatment Based on Absolute Risk and the Potential for Benefit , 1993, Annals of Internal Medicine.

[80]  P Barham,et al.  Management of raised blood pressure in New Zealand: a discussion document. , 1993, BMJ.

[81]  A. Sedman,et al.  Angiotensin-converting enzyme inhibitor fetopathy. , 1993, Journal of the American Society of Nephrology : JASN.

[82]  B. Pitt,et al.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.

[83]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[84]  D. Felson,et al.  Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. , 1991, JAMA.

[85]  G. Lamas,et al.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. , 1988, The New England journal of medicine.

[86]  K. Silberbauer,et al.  Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. , 1982, British journal of clinical pharmacology.

[87]  A. Helgeland Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. , 1980, The American journal of medicine.

[88]  K. Kushima [Hypertension in women]. , 1966, Saishin igaku. Modern medicine.

[89]  S. Oparil,et al.  Health Outcomes Associated with Calcium Antagonists , 2001, Current hypertension reports.

[90]  O. Jolobe Angiotensin-converting enzyme inhibitors. , 1995, British journal of hospital medicine.

[91]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[92]  W. Willett,et al.  A prospective study of nutritional factors and hypertension among US women. , 1989, Circulation.

[93]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[94]  A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. , 1982, JAMA.

[95]  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. , 1967, JAMA.